Healthcare >> Analyst Interviews >> March 6, 2000
TWST: Matt, what are the key elements of the approach that you at SG SCOTT D. WILKIN is a Director of Medical Technology Institutional
Research at SG Cowen Securities. His previous experience includes three
years as a Medical Technology Analyst at Warburg Dillon Read, two years
as Manager of Business Development at Dura Pharmaceuticals, and four
years as Market Research Consultant at Boston Biomedical Consultants.
Mr. Wilkin earned his Bachelor's degree in Biochemistry with a minor in
Economics from Bowdoin College and an MBA from the Harvard Business
MATTHEW J. DODDS joined SG Cowen in 1999 to cover the medical supplies
and technology industry, and is Managing Director. Prior to joining SG
Cowen, he spent the past four and a half years at UBS Warburg as a
medical supplies and technology analyst, with a focus on the cardiology,
ophthalmology and surgical fields. Prior to UBS Warburg, he spent two
years as an associate at Kidder Peabody covering the medical supplies
and technology industry. Prior to Kidder Peabody, he spent two years in
Paine Webber's Equity Research department as Hard Dollar Sales Manager.
He received a BS degree in Industrial Management from Carnegie Mellon
University in 1991. Profile
Cowen take to investing in medical technology?
Mr. Dodds: I would say the first thing Scott and I would tell you is,